Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
Letter From The Editor

This was a busy week in the GLP-1 arena. An FDA advisory panel last week overwhelmingly recommended approval of Novo Nordisk's latest weight-loss drug, Saxenda. This medication, which is liraglutide 3 mg, was recommended as an adjunct to diet and exercise in adults with a BMI of 30 or more, or 27 or more with at least one weight-related comorbidity.

Eli Lilly also got approval for their once-weekly dulaglutide based on six clinical trials involving a total of 3,342 patients who received the drug. It was studied as a stand-alone therapy and in combination with metformin, sulfonylurea, thiazolidinedione, and prandial insulin.

For those of you who want to know more be sure to check out our September GLP-1 Special Edition coming out next week.

The idea of using a GLP-1 analogs for weight loss is not new and if you check out Item #6, losing weight makes extra sense when you see how much money we save on diabetes patients who have healthy lifestyle habits.

We all know that whenever we talk weight loss, the words 'diet' and 'exercise' always come into play. This week, our exercise guru Dr. Sheri Colberg shares the first of three columns on why daily movement improves brain health as well as blood sugars. In Part 1, she discusses Gene Activation and More.


With a day packed full of education, motivational tools, one-on-one sessions, and workshops, the TCOYD health fair is a great way to get your patients to take better care of their health and themselves. 
From "Vietnam veterans who developed type 2 diabetes after exposure to Agent Orange recount their struggles. Plus, Chef Michel Nischan in the dLife kitchen with a cheesy veggie favorite, and Jim Turner in the dentist's chair." Sundays live online at at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at
We can make a difference!

Dave Joffe, Editor-in-chief

  … Read More

Scroll down for items in the current newsletter


FDA Approves Once-Weekly Dulaglutide for Type 2 Diabetes

Once-weekly dulaglutide was approved based on six clinical trials involving a total of 3,342 patients who received the drug. It was studied as a stand-alone therapy and in combination with metformin, sulfonylurea, thiazolidinedione, and prandial insulin. 

Tool for your Practice

"Your School Your Rights" Patient Handout for Parents of Children with Diabetes

Every parent with a child with diabetes needs to have this information. This updated four-panel brochure explains the legal protections for and rights of students with diabetes. Includes a school discrimination checklist and information on how to get help.

Product of the Week

MedPockets for Women with Diabetes 

For women patients who are looking for a convenient way to carry their diabetes meds and other necessities. Includes four built-in pockets perfect for insulin pumps, glucose meters, prosthesis, other essential health items, or personal items including cell phones, money, keys, credit cards, etc. Fashionable, comfortable and convenient. Keep daily medical essentials in a discreet, secure, convenient way.





For Your Patients: Why Daily Movement Improves Your Brain Health, Part 1: Gene Activation and More


By Sheri Colberg, PhD 

When it comes to brain health, nothing beats physical activity and all types of daily movement for having a powerful effect. Having a healthy brain is essential to living a long life well, which should be the goal for everyone, not just people with diabetes. Here are some reasons why your brain needs for you to be active.... Full article






Test Your Knowledge Question #747

According to the American Diabetes Association, an impaired fasting blood glucose level is in the range of:

A. 80 – 195 mg/dL
B. 90 – 115 mg/dL
C. 100 – 125 mg/dL

For the complete question and answer, just follow this link.



Quality Assurance Editor – Diabetes in Control

Seeking practicing or retired medical professional (MD, NP, PA, RN, PharmD and/or CDE) experienced in treating diabetes patients OR hands-on medical editor with deep diabetes technical knowledge. Approximately 4 hours per week. Compensation depends on experience. Email cover and resume to



Diabetes In Control Has Over 15000 Studies & Articles In Our Archives

Quote of the Week!

"The price of success is hard work, dedication to the job at hand, and the determination that whether we win or lose, we have applied the best of ourselves to the task at hand." 

          .............Vince Lombardi

Diabetes in Control gratefully acknowledges the assistance of the following University of Florida pharmacy doctoral candidate in the preparation of this week's newsletter: 

Simi A. Lukose, Florida A&M University

Mai Do, Florida A&M University


Arpita Patel, Florida A&M University 


Cast Your Vote
Now that once-weekly dulaglutide has been approved, will you be prescribing it?
CME/CE of the Week
Jeffrey M. Robbins, DPM

Category: Wound Care
Credits: .5


Search Articles On Diabetes In Control